Video

Dr. Buffington on The Use of Fusion MRI in Prostate Cancer

Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discussed the use of fusion MRI in prostate cancer with OncLive during the LUGPA Annual Meeting.

Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discusses the use of fusion magnetic resonance imaging (MRI) in prostate cancer with OncLive during the LUGPA Annual Meeting.

Fusion MRI is typically used for a second biopsy, in patients with prostate cancer who are on active surveillance, or patients who have had a negative biopsy in the past, but their PSA is still rising, Buffington says. The MRI helps target an area that may have been missed on a prior biopsy.

The images from the MRI are then fused with the images on the ultrasound, which allows urologists to better target and bioposy the area.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Louis Crain Garrot, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Bradley C. Carthon, MD, PhD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center